Cell therapy developer
Appears in 1 story · Last updated Nov 3, 2026
Subsidiary of Ayrmid; would absorb Karyopharm if the deal closes
Karyopharm Therapeutics filed for Chapter 11 bankruptcy on November 2, 2026, and agreed to sell itself to Ayrmid Ltd., the Irish parent of cell therapy maker Gamida Cell. Ayrmid is the lead bidder, not the guaranteed buyer: the filing sets up a court-supervised auction where other offers can compete.
Updated 1 hour ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
